Recursion Pharmaceuticals Analyst Ratings
Recursion Pharmaceuticals Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/09/2023 | 186.81% | Needham | $17 → $15 | Maintains | Buy |
09/05/2023 | 225.05% | Needham | → $17 | Reiterates | Buy → Buy |
08/09/2023 | 225.05% | Needham | → $17 | Reiterates | Buy → Buy |
07/21/2023 | 225.05% | Needham | → $17 | Reiterates | Buy → Buy |
07/18/2023 | 225.05% | Needham | → $17 | Reiterates | Buy → Buy |
07/13/2023 | 110.33% | Morgan Stanley | $8 → $11 | Maintains | Equal-Weight |
07/13/2023 | 186.81% | Keybanc | $12 → $15 | Maintains | Overweight |
07/12/2023 | 225.05% | Needham | → $17 | Reiterates | Buy → Buy |
07/12/2023 | 530.98% | Berenberg | $33 → $33 | Reiterates | Buy → Buy |
05/09/2023 | 225.05% | Needham | → $17 | Reiterates | → Buy |
05/09/2023 | 129.45% | Keybanc | $20 → $12 | Maintains | Overweight |
04/18/2023 | 225.05% | Needham | → $17 | Reiterates | → Buy |
03/16/2023 | 225.05% | Needham | → $17 | Initiates Coverage On | → Buy |
01/23/2023 | 52.96% | SVB Leerink | $9 → $8 | Maintains | Market Perform |
11/09/2022 | 72.08% | Goldman Sachs | $8 → $9 | Maintains | Neutral |
10/25/2022 | 72.08% | SVB Leerink | $10 → $9 | Maintains | Market Perform |
09/16/2022 | 282.41% | Keybanc | → $20 | Initiates Coverage On | → Overweight |
08/11/2022 | 52.96% | Goldman Sachs | $7 → $8 | Maintains | Neutral |
05/24/2022 | 33.84% | Goldman Sachs | $9 → $7 | Maintains | Neutral |
05/12/2022 | 72.08% | Goldman Sachs | $10 → $9 | Maintains | Neutral |
04/18/2022 | — | B of A Securities | Downgrades | Buy → Neutral | |
03/24/2022 | 91.2% | Goldman Sachs | $32 → $10 | Maintains | Neutral |
03/04/2022 | 91.2% | SVB Leerink | $32 → $10 | Downgrades | Outperform → Market Perform |
12/08/2021 | 511.85% | SVB Leerink | $30 → $32 | Maintains | Outperform |
09/21/2021 | 607.46% | Berenberg | → $37 | Initiates Coverage On | → Buy |
08/16/2021 | 473.61% | SVB Leerink | $33 → $30 | Maintains | Outperform |
05/11/2021 | 530.98% | SVB Leerink | → $33 | Initiates Coverage On | → Outperform |
05/11/2021 | 492.73% | B of A Securities | → $31 | Initiates Coverage On | → Buy |
05/11/2021 | 511.85% | JP Morgan | → $32 | Initiates Coverage On | → Neutral |
05/11/2021 | 550.1% | Goldman Sachs | → $34 | Initiates Coverage On | → Neutral |
05/11/2021 | 588.34% | Keybanc | → $36 | Initiates Coverage On | → Overweight |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
11/09/2023 | 186.81% | 尼德姆 | 17 美元 → 15 美元 | 維護 | 買 |
09/05/2023 | 225.05% | 尼德姆 | → 17 美元 | 重申 | 購買 → 購買 |
08/09/2023 | 225.05% | 尼德姆 | → 17 美元 | 重申 | 購買 → 購買 |
07/21/2023 | 225.05% | 尼德姆 | → 17 美元 | 重申 | 購買 → 購買 |
07/18/2023 | 225.05% | 尼德姆 | → 17 美元 | 重申 | 購買 → 購買 |
07/13/2023 | 110.33% | 摩根士丹利 | 8 美元 → 11 美元 | 維護 | 重量相等 |
07/13/2023 | 186.81% | Keybanc | 12 美元 → 15 美元 | 維護 | 超重 |
07/12/2023 | 225.05% | 尼德姆 | → 17 美元 | 重申 | 購買 → 購買 |
07/12/2023 | 530.98% | 貝倫貝格 | 33 美元 → 33 美元 | 重申 | 購買 → 購買 |
05/09/2023 | 225.05% | 尼德姆 | → 17 美元 | 重申 | → 購買 |
05/09/2023 | 129.45% | Keybanc | 20 美元 → 12 美元 | 維護 | 超重 |
04/18/2023 | 225.05% | 尼德姆 | → 17 美元 | 重申 | → 購買 |
03/16/2023 | 225.05% | 尼德姆 | → 17 美元 | 啓動覆蓋範圍開啓 | → 購買 |
2023 年 1 月 23 日 | 52.96% | SVB Leerink | 9 美元 → 8 美元 | 維護 | 市場表現 |
11/09/2022 | 72.08% | 高盛 | 8 美元 → 9 美元 | 維護 | 中立 |
10/25/2022 | 72.08% | SVB Leerink | 10 美元 → 9 美元 | 維護 | 市場表現 |
2022 年 9 月 16 日 | 282.41% | Keybanc | → 20 美元 | 啓動覆蓋範圍開啓 | → 超重 |
08/11/2022 | 52.96% | 高盛 | 7 美元 → 8 美元 | 維護 | 中立 |
2022 年 5 月 24 日 | 33.84% | 高盛 | 9 美元 → 7 美元 | 維護 | 中立 |
05/12/2022 | 72.08% | 高盛 | 10 美元 → 9 美元 | 維護 | 中立 |
04/18/2022 | — | B of A 類證券 | 降級 | 買入 → 中性 | |
2022 年 3 月 24 日 | 91.2% | 高盛 | 32 美元 → 10 美元 | 維護 | 中立 |
03/04/2022 | 91.2% | SVB Leerink | 32 美元 → 10 美元 | 降級 | 跑贏大盤 → 市場表現 |
2021 年 8 月 12 日 | 511.85% | SVB Leerink | 30 美元 → 32 美元 | 維護 | 跑贏大盤 |
09/21/2021 | 607.46% | 貝倫貝格 | → 37 美元 | 啓動覆蓋範圍開啓 | → 購買 |
2021 年 8 月 16 日 | 473.61% | SVB Leerink | 33 美元 → 30 美元 | 維護 | 跑贏大盤 |
05/11/2021 | 530.98% | SVB Leerink | → 33 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
05/11/2021 | 492.73% | B of A 類證券 | → 31 美元 | 啓動覆蓋範圍開啓 | → 購買 |
05/11/2021 | 511.85% | 摩根大通 | → 32 美元 | 啓動覆蓋範圍開啓 | → 中立 |
05/11/2021 | 550.1% | 高盛 | → 34 美元 | 啓動覆蓋範圍開啓 | → 中立 |
05/11/2021 | 588.34% | Keybanc | → 36 美元 | 啓動覆蓋範圍開啓 | → 超重 |
What is the target price for Recursion Pharmaceuticals (RXRX)?
Recursion Pharmicals(RXRX)的目標價格是多少?
The latest price target for Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by Needham on November 9, 2023. The analyst firm set a price target for $15.00 expecting RXRX to rise to within 12 months (a possible 186.81% upside). 14 analyst firms have reported ratings in the last year.
Needham於2023年11月9日公佈了遞歸製藥(納斯達克股票代碼:RXRX)的最新目標股價。該分析公司將目標股價定爲15.00美元,預計RXRX將在12個月內升至12個月內(可能上漲186.81%)。去年有14家分析公司公佈了評級。
What is the most recent analyst rating for Recursion Pharmaceuticals (RXRX)?
Recursion Pharmicals(RXRX)的最新分析師評級是多少?
The latest analyst rating for Recursion Pharmaceuticals (NASDAQ: RXRX) was provided by Needham, and Recursion Pharmaceuticals maintained their buy rating.
Recursion Pharmicals(納斯達克股票代碼:RXRX)的最新分析師評級由Needham提供,Recursion Pharmicals維持買入評級。
When is the next analyst rating going to be posted or updated for Recursion Pharmaceuticals (RXRX)?
Recursion Pharmicals(RXRX)的下一個分析師評級何時公佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Recursion Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Recursion Pharmaceuticals was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Recursion Pharmicals的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。Recursion Pharmicals的最新評級是在2023年11月9日發佈的,因此您應該預計下一個評級將在2024年11月9日左右公佈。
Is the Analyst Rating Recursion Pharmaceuticals (RXRX) correct?
分析師對遞歸藥業 (RXRX) 的評級是否正確?
While ratings are subjective and will change, the latest Recursion Pharmaceuticals (RXRX) rating was a maintained with a price target of $17.00 to $15.00. The current price Recursion Pharmaceuticals (RXRX) is trading at is $5.23, which is out of the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但遞歸製藥(RXRX)的最新評級維持不變,目標股價爲17.00美元至15.00美元。遞歸製藥(RXRX)目前的交易價格爲5.23美元,超出了分析師的預期區間。